Abstract 1774P
Background
In a recently published manuscript we demonstrated significant decreases in mental distress, anxiety and depression compared to standard of care following a 6m daily comprehensive program developed with patient engagement. Here we conduct secondary analyses examining the effects of this Prostate Cancer-Patient Empowerment Program (PC-PEP) on patient-reported urinary, bowel, sexual, hormonal and physical function among men scheduled for curative prostate cancer (PC) treatment.
Methods
This crossover randomized clinical trial evaluated 128 men aged 50–82 yr scheduled for curative prostate cancer surgery or radiotherapy (± hormone), 66 received the 6-mo PC-PEP intervention and 62 were randomized to standard of care for 6m and received PC-PEP to the end of the year. PC-PEP comprises regular physical strength and PFMT training, daily dietary advice, bio-feedback stress reduction, and social networking. Weekly online compliance surveys, the International Prostate Symptom Score (IPSS), Expanded Prostate Cancer Index Composite (EPIC), and SF-12 at baseline, 6 and 12m were completed. MLM analyses were used to evaluate the results.
Results
Baseline patient characteristics and outcomes between the two groups were comparable, and weekly compliance for PC-PEP was high among both groups (early v. late intervention). At six months, the PC-PEP group had improved IPSS bother score, EPIC Urinary Incontinence, EPIC Irritative/Obstructive score, physical fitness (lower weight and BMI), SF-12 physical, and mental health function when compared to the control group (p=0.004, p=0.001, p=0.008, p=0.001, p=0.002, and p=0.003 respectively). Analyses revealed that providing the intervention early or late was equally beneficial to patients. No other significant results emerged.
Conclusions
PC-PEP significantly improves lower urinary tract symptoms, physical function and overall quality of life among men scheduled for curative PC treatment compared to standard of care. The program is being currently tested in an international phase 4 trial.
Clinical trial identification
NCT03660085.
Editorial acknowledgement
Legal entity responsible for the study
Nova Scotia Health Authority, Canada.
Funding
Research Nova Scotia Establishment Grant (#2215).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14